Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 10/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 1.00 |
| ▸ | RAF1 | P04049 | 3/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | THRB | P10828 | 3/20 | 0.75 |
| ▸ | HTT | P42858 | 3/20 | 0.75 |
| ▸ | RAB9A | P51151 | 3/20 | 0.75 |
| ▸ | GALK1 | P51570 | 3/20 | 0.75 |
| ▸ | BLM | P54132 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181779 | 0.88 | TDP2 (1.00) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL3472993 | 0.87 | KDM4C (1.00) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL2179691 | 0.86 | KDM4C (1.00) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL2180580 | 0.86 | TDP2 (1.00) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL14020030 | 0.85 | TDP2 (0.73) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL13272626 | 0.85 | TDP2 (0.74) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL3471238 | 0.85 | TDP2 (0.80) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL2184252 | 0.84 | TDP2 (0.77) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL2186422 | 0.83 | KDM4C (1.00) | TDP2KDM4CRAF1MAP2K1SIRT1 | |
| SCHEMBL2183454 | 0.83 | TDP2 (0.76) | TDP2KDM4CRAF1MAP2K1SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | claimed |
| US-20210113570-A1 | INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2021-04-22 | — | — | US | disclosed |
| US-10888564-B2 | Inhibitors of HIV-1 integrase multimerization | INSTITUTE FOR CANCER RESEARCH (US) | 2021-01-12 | — | — | US | disclosed |
| WO-2018140762-A1 | INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION | INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-1587806-B1 | PYRIMIDO 5,4-E 1,2,4 TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113570-A1 | INHIBITORS OF HIV-1 INTEGRASE MULTIMERIZATION | PIK3CA, PIK3CB, SAMHD1 | TDP2 81/4885KDM4C 1507/4885RAF1 2319/4885 |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | TDP2 3811/4885KDM4C 1158/4885RAF1 3628/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | TDP2 685/4885KDM4C 3280/4885RAF1 2577/4885 |
| US-10888564-B2 | Inhibitors of HIV-1 integrase multimerization | CDK7, TYMP, CDC7 | TDP2 141/4885KDM4C 1898/4885RAF1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.